USNAConsumer Defensive · Packaged FoodsTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 10 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores USANA Health Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (21): The shares have been drifting down relative to others.
The bullish and bearish analyst opinions on USNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Feb 2025 | DA Davidson | Maintains | Neutral | $38 → $36 |
| 27 Feb 2025 | DA Davidson | Maintains | Neutral | — |
| 2 Jan 2025 | DA Davidson | Maintains | Neutral | — |
| 23 Oct 2024 | DA Davidson | Maintains | Neutral | — |
| 25 July 2024 | DA Davidson | Maintains | Neutral | — |
| 7 May 2024 | DA Davidson | Maintains | Neutral | — |
| 22 Feb 2024 | DA Davidson | Maintains | Neutral | — |
| 25 Oct 2023 | DA Davidson | Maintains | Neutral | — |
| 26 Apr 2023 | DA Davidson | Maintains | Neutral | — |
| 13 Feb 2023 | DA Davidson | Maintains | Neutral | — |
| 27 Oct 2022 | DA Davidson | Maintains | Neutral | — |
| 28 July 2022 | DA Davidson | Maintains | Neutral | — |
| 12 July 2022 | DA Davidson | Maintains | Neutral | — |
| 7 July 2022 | Jefferies | Downgrade | Underperform | — |
| 27 Apr 2022 | DA Davidson | Maintains | Neutral | — |
| 14 Apr 2022 | DA Davidson | Initiates | Neutral | — |
| 10 Feb 2021 | Roth Capital | Maintains | Buy | — |
| 17 Dec 2020 | Roth Capital | Initiates | Buy | — |
| 22 Aug 2019 | Jefferies | Initiates | Hold | — |
| 3 July 2019 | Sidoti & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. USNA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 89% of US stocks
Cheaper than 84% of US stocks
Cheaper than 57% of US stocks
Higher than 20% of US stocks
Higher than 20% of US stocks
Higher than 88% of US stocks
Higher than 53% of US stocks
Higher than 27% of US stocks
Higher than 39% of US stocks
Higher than 69% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
The rank is the raw material. Whether the rules would actually own USANA Health Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Usana Health Sciences reported second-quarter earnings and sales that came in well below expectations. The company now expects to record a loss for the full year.
Why it matters — A full-year loss forecast and below-expectation quarterly results signal a meaningful deterioration in Usana's near-term financial outlook for shareholders and prospective investors.
USANA Health Sciences reported that its core nutritional business met expectations in Q2 2026, but near-term challenges at its Hiya and Rise Wellness ventures led the company to lower its full-year outlook.
Why it matters — USNA watchers would care because the lowered full-year outlook signals headwinds from the company's wellness ventures despite a stable core business.
USANA Health Sciences shares fell sharply after second-quarter earnings. The direct selling business continued to shrink, and its growth brands Hiya and Rise Wellness underperformed, with revenues plummeting and their 2026 guidance cut substantially.
Why it matters — USNA watchers would care because the company's two growth brands struggled and their outlook was reduced, suggesting limited remaining growth drivers for the business.
Seeking Alpha published the transcript of USANA Health Sciences, Inc.'s Q2 2026 earnings call. The item comprises the company's second-quarter 2026 earnings call presentation.
Why it matters — A USNA watcher would care because the earnings call transcript provides direct details on the company's second-quarter 2026 financial results and management commentary.
On Aug. 5, 2026, USANA Health Sciences Chairman and CEO Kevin Guest encouraged people to intentionally notice, create, and share moments of genuine happiness at work and home during August's Happiness Happens Month. He commented that happiness is not a prize received after everything goes perfectly, citing his book All the Right Reasons.
Why it matters — USNA watchers would care because the item showcases the CEO's public leadership messaging and brand ties to wellness and lifestyle themes.
As at 10 Aug 2026, USANA Health Sciences, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No analyst covering USANA Health Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for USNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
USANA Health Sciences, Inc. returned -53.1% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Usana Health Sciences, Inc. is a prominent player in the healthcare and wellness sector, primarily focused on the development and distribution of nutritional supplements and personal care products.
The most recent item we track (The Motley Fool, 9 Aug 2026): "Why Usana Health Sciences Stock Plummeted This Week". Usana Health Sciences reported second-quarter earnings and sales that came in well below expectations. The company now expects to record a loss for the full year.
Usana Health Sciences, Inc. is a prominent player in the healthcare and wellness sector, primarily focused on the development and distribution of nutritional supplements and personal care products. The company is renowned for its high-quality vitamins, dietary supplements, and skin and personal care items, aiming to enhance well-being and support healthy living. Usana operates on a global scale, selling its products through a direct selling model, which not only markets its portfolio but also empowers entrepreneurs around the world. Established in 1992, Usana Health Sciences has carved a niche in the wellness industry by prioritizing scientific research and development to ensure product efficacy and safety. The company's innovative approach and dedication to quality have made it a trusted name among health-conscious consumers and medical professionals alike. Usana plays a significant role in the broader health and wellness market, contributing to the global trend towards preventive health measures and personalized healthcare solutions.
CEO Mr. Jim Brown · 1,700 employees · United States · https://www.usana.com